NCT05946798 is a EARLY_PHASE1 clinical trial of Acetylcholine in Gestational Diabetes, sponsored by Anna Stanhewicz, PhD.

Who is sponsoring NCT05946798?

NCT05946798 is sponsored by Anna Stanhewicz, PhD.

What drugs are being tested in NCT05946798?

Interventions in NCT05946798: Acetylcholine, Insulin aspart.

What condition does NCT05946798 study?

NCT05946798 studies Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function.

Is NCT05946798 still recruiting?

NCT05946798 is currently recruiting now. Last updated 13 May 2025.

Last reviewed 2025-05-13 · How we verify

NCT05946798

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM

Recruiting now EARLY_PHASE1 Last updated 13 May 2025

What this trial tests

EARLY_PHASE1 trial testing Acetylcholine in Gestational Diabetes in 40 participants. Currently enrolling.

Timeline

30 August 2023

Primary endpoint
30 June 2027

1 June 2028

Quick facts

Lead sponsor	Anna Stanhewicz, PhD
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	40
Start date	30 August 2023
Primary completion	30 June 2027
Estimated completion	1 June 2028
Sites	1 location across United States

Drugs / interventions tested

Acetylcholine (ACETYLCHOLINE) — full drug profile →
Insulin aspart (INSULIN ASPART) — full drug profile →

Conditions studied

Gestational Diabetes — all drugs for Gestational Diabetes →
Oxidative Stress — all drugs for Oxidative Stress →
Vascular Endothelial Function — all drugs for Vascular Endothelial Function →

Sponsor

Anna Stanhewicz, PhD — full company profile →

Who can join

Adults 18 to 50, female only, with Gestational Diabetes or Oxidative Stress. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this investigation is to examine NADPH oxidase as a source of reactive oxygen species contributing to aberrant microvascular function in otherwise healthy women with a history of GDM.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Local apocynin improves acetylcholine- but not insulin-mediated vasodilation in the cutaneous microvasculature of women with a history of gestational diabetes.
Maurer GS, O'Neill BT, Jalal DI, Stanhewicz AE. · · 2026 · PMID 41758055 · DOI 10.1152/japplphysiol.01080.2025

Verify or expand the search:

Other trials of Acetylcholine

Trials testing the same drug.

NCT06520982 — Early Neurovascular Adaptations in Aging Women · EARLY_PHASE1 · recruiting
NCT06443151 — Role of Endothelial Function in SCI CVD Risk · recruiting
NCT05946785 — Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes · EARLY_PHASE1 · recruiting
NCT05653973 — Prenatal Aspirin and Postpartum Vascular Function · EARLY_PHASE1 · recruiting
NCT04918563 — Endothelium Dependent and Non-dependent Vasodilatation in Human Gingiva · NA · completed

Other recruiting trials for Gestational Diabetes

Currently open trials in the same condition.

NCT07171684 — Single vs Multi-Dose Insulin for Glycemic Control (SUGAR) · NA · recruiting
NCT07314944 — Maternal Sleep and Lifestyle, Metabolic Health, and Perinatal Outcomes in Gestational Diabetes · recruiting
NCT06571487 — Growth Hormone Resistance of Beta-cells · recruiting
NCT07336914 — Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes · NA · recruiting
NCT07174245 — Pregnancy and Postpartum CGM in GDM · recruiting

Other Anna Stanhewicz, PhD trials

Trials by the same sponsor.

NCT07345845 — MR and Inflammation After Preeclampsia · EARLY_PHASE1 · active not recruiting
NCT06911372 — The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy · Phase 1 · recruiting
NCT06749418 — Vascular Effects of High-Salt After Preeclampsia · EARLY_PHASE1 · recruiting
NCT05917587 — Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes · EARLY_PHASE1 · recruiting
NCT06157580 — Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05946798 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anna Stanhewicz, PhD
Last refreshed: 13 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05946798.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing